Protara Therapeutics (TARA) Free Cash Flow (2013 - 2026)

Protara Therapeutics (TARA) has reported Free Cash Flow for 14 consecutive years, with -$21.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 44.63% year-over-year to -$21.3 million; the TTM figure through Mar 2026 stood at -$63.0 million (down 56.85% YoY), while the FY2025 annual figure was -$56.5 million, down 57.39% from the prior year.
• Free Cash Flow retreated to -$21.3 million in Q1 2026 per TARA's latest filing, from -$17.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$5.0 million in Q4 2022 and bottomed at -$21.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$10.5 million across 5 years, with a median of -$9.4 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 47.52% — and 2023, when it sank 82.97%.
• Protara Therapeutics' Free Cash Flow stood at -$5.0 million in 2022, then tumbled by 72.89% to -$8.7 million in 2023, then slipped by 6.99% to -$9.3 million in 2024, then tumbled by 82.36% to -$17.0 million in 2025, then decreased by 25.74% to -$21.3 million in 2026.
• Business Quant data shows TARA's Free Cash Flow at -$21.3 million in Q1 2026, -$17.0 million in Q4 2025, and -$12.5 million in Q3 2025.